RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Topical Administration of a Marine Oil Rich in Pro-Resolving Lipid Mediators Accelerates Wound Healing in Diabetic db/db Mice through Angiogenesis and Macrophage Polarization
[EN] Impaired wound healing in patients with type 2 diabetes (DM2) is characterized by chronic inflammation, which delays wound closure. Specialized pro-resolving lipid mediators (SPMs) are bioactive molecules produced from essential polyunsaturated fatty acids (PUFAs), principally omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). SPMs are potent regulators of inflammation and have been used to suppress chronic inflammation in peripheral artery disease, non-alcoholic fatty liver disease, and central nervous system syndromes. LIPINOVA® is a commercially available safe-grade nutritional supplement made from a fractionated marine lipid concentrate derived from anchovy and sardine oil that is rich in SPMs and EPA, as well as DHA precursors. Here, we assessed the effect of LIPINOVA® in wound dressing applications. LIPINOVA® showed biocompatibility with keratinocytes and fibroblasts, reduced the abundance of pro-inflammatory macrophages (M¿1), and promoted in vitro wound closure. Daily application of the marine oil to open wounds made by punch biopsy in db/db mice promoted wound closure by accelerating the resolution of inflammation, inducing neoangiogenesis and M¿1/M¿2 macrophage polarization. In conclusion, LIPINOVA® displays pro-resolutive properties and could be exploited as a therapeutic agent for the treatment of diabetic ulcers., This work was supported by the RETICS Program (RD16/0011/0004 and RD16/0011/0005) of the Instituto de Salud Carlos III, co-funded by FEDER 'una manera de hacer Europa,' and by PROJECT RESOLTEX (RTC-2015-4185-1) of the Ministerio de Economia y Competitividad through the RETOS program. It was also supported by grant ACIF/2020/352 to E.A.-P. from the Conselleria de Innovacion, Universidades, Ciencia, y Sociedad Digital and co-financed by the European Union through the Operational Program of the European Regional Development Fund (FEDER) of the Valencian Community 2014-2020, and from the Instituto de Salud Carlos III, co-funded by FEDER, to P.S (PI19/00245) and B.P. (PI19/00501).
Proyecto:
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19/00245
,
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19/00501
,
Ministerio de Economía y Competitividad RD16/0011/0004
,
Ministerio de Economía y Competitividad RD16/0011/0005
,
Ministerio de Economía y Competitividad RTC-2015-4185-1G03182870C.VALENCIANA
,
Generalitat Valenciana ACIF/2020/352